Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (11)
Type
(
1 selected
)
Type
Guidance (304)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (1)
Health technology evaluations (6)
Highly specialised technologies guidance (1)
Interventional procedures guidance (6)
Medical technologies guidance (5)
Technology appraisal guidance (285)
Apply filters
Showing 191 to 200 of 304
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer TS ID 10690
Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953
Technology appraisal guidance
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID6399
Technology appraisal guidance
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]
Technology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808
Technology appraisal guidance
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]
Technology appraisal guidance
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]
Technology appraisal guidance
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Technology appraisal guidance
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810
Technology appraisal guidance
Previous page
1
…
18
19
Current page
20
21
22
…
31
Page
20
of
31
Next page
Results per page
10
25
50
All
Back to top